Pacific Edge shares more than double on US healthcare news

Pacific Edge shares more than double on US healthcare news
Brent Melville
Pacific Edge shares more than doubled in value on confirmation of acceptance under a key US medical regulation for its Cxbladder cancer test. The shares jumped as high as 68 cents from 27 cents yesterday, and were recently at 55 cents, up 104 percent and valuing the company at $379.3 million. The successful standard of care rating from the US Centres for Medicare and Medicaid Services means Pacific Edge will be reimbursed at a rate of US$760 per test from July 1, 2020.  The CMS provides healthcare coverage for all US citizens over the...

More Services

Creative solutions needed to keep NZ workers
Economy

Creative solutions needed to keep NZ workers

Robert Walters sees talent migration potentially getting worse in 2025.

‘Battle-hardened’ Trade Window eyes growth
Markets

‘Battle-hardened’ Trade Window eyes growth

The customs software minnow has weathered the storm. What next?

Pattrick Smellie 21 Nov 2024
Crimson big enough for ASX IPO: Beaton
Finance

Crimson big enough for ASX IPO: Beaton

A US market listing at a greater scale looks more likely.

Pattrick Smellie 06 Nov 2024
CoreLogic data suggests property market floor is nigh
Property

CoreLogic data suggests property market floor is nigh

Broad economic trends underpin the latest figures, CoreLogic's economist says.